MARKET

RARE

RARE

Ultragenyx Pharm
NASDAQ
33.82
-0.79
-2.28%
After Hours: 33.82 0 0.00% 16:53 07/10 EDT
OPEN
34.61
PREV CLOSE
34.61
HIGH
34.81
LOW
32.72
VOLUME
1.58M
TURNOVER
--
52 WEEK HIGH
42.37
52 WEEK LOW
18.29
MARKET CAP
3.33B
P/E (TTM)
-5.5421
1D
5D
1M
3M
1Y
5Y
1D
Ultragenyx releases 2025 impact report outlining ESG progress across six pillars
PUBT · 2d ago
Ultragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value Benchmarks - Has The Bull Case Changed?
Simply Wall St · 2d ago
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
Barchart · 3d ago
Ultragenyx Pharma Is Maintained at Outperform by RBC Capital
Dow Jones · 3d ago
Ultragenyx Pharma Price Target Raised to $40.00/Share From $35.00 by RBC Capital
Dow Jones · 3d ago
RBC Capital Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $40
Benzinga · 3d ago
Ultragenyx: Favorable Risk-Reward Ahead of GTX-102 ASPIRE Readout, Analyst Reiterates Buy and $72 Price Target
TipRanks · 3d ago
Ultragenyx Executive Makes Head-Turning Move With Fresh Stock Sale
TipRanks · 4d ago
More
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH.

Webull offers Ultragenyx Pharmaceutical Inc stock information, including NASDAQ: RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.